PHOTOCURE ANNOUNCES AGREEMENT WITH US FDA FOR CEVIRA PHASE 3 REGISTRATION PROGRAM

Share this article
Published: 10 August 2015Product Announcements

Oslo, Norway, 10 August, 2015: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces today the approval of the Special Protocol Agreement (SPA) from the US FDA on the design of the Phase 3 clinical registration program for Cevira, which is in development for the treatment of high grade pre-cancerous lesions of the cervix. The SPA defines the size, design and analysis of clinical trials that will form the primary basis of approval.

In response to Photocure's request for a special protocol assessment (SPA), the US FDA has agreed that the design and planned analysis of the pivotal Phase 3 protocols address the objectives in support of a regulatory submission. Ensuring regulatory alignment before initiating the Phase 3 registration trials reduces the risk of the development program and is an important milestone in the continued development of Cevira.

Kjetil Hestdal, President & CEO of Photocure, said: "Gaining alignment with the FDA on the Cevira registration program through the SPA process is a significant milestone in the continued development of this breakthrough technology. Cevira will offer a convenient and effective alternative to surgery in the large number of affected women globally, while preserving fertility and avoiding the potential for future neonatal morbidity and mortality which results from surgery."

With alignment with FDA on Phase 3 clinical studies now obtained, Photocure plans to finalize necessary documentation for the Cevira device to ensure readiness for the Phase 3 trial.  The Phase 3 registration program will consist of two identical double blind, randomized trials, each with approximately 200 patients, comparing Cevira to placebo in women with biopsy proven high-grade cervical lesions. The primary endpoint will be clearance of the high-grade lesion, as determined by an independent panel of pathologists, at six months.

For further information, please contact:
Photocure

President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email: kh@photocure.no

CFO Erik Dahl
Tel: +47 450 55 000, Email: ed@photocure.com

About Photocure ASA

Photocure ASA, headquartered in Oslo, Norway, is a specialty pharmaceutical company and world leader in photodynamic technology. Based on our unique proprietary Photocure Technology® platform, Photocure develops and commercializes highly selective and effective solutions in disease areas with high unmet medical need, such as bladder cancer, HPV and precancerous cervical lesions, colorectal cancer and skin conditions. Our aim is to provide solutions that can improve health outcomes for patients worldwide. Photocure is listed on the Oslo Stock Exchange (OSE: PHO). Information about Photocure is available at www.photocure.com.

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)
Share this article

News and events